The success of first-generation EGFR inhibitors, such as gefitinib and erlotinib, in the treatment of EGFR-mutated non-small cell lung cancer has underscored the therapeutic potential of EGFR-targeted agents [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.